Valtech has a specialized team to perform regular market and valuation research to provide valuable insights to our exclusive clients
Given the uncertainties associated with valuation of biotech enterprises, valuers can put stronger effort in benchmarking. A solid pool of comparable listed companies and comparable transaction will be highly useful to support valuation assumptions at different clinical trial phase.
Why Consider ESG in Valuation? Different environmental disasters, social unrest and the governance amid COVID-19 makes ESG reports more important to value a company. In order to increase comparability of ESG reports, different institutions include the IFRS foundation, the CFA Institute and the EFRAG are now considering to develop a global reporting standard for
The latest 2020 edition of the International Valuation Standards (IVS) marks an important milestone towards harmonising valuation practice worldwide. Valtech has been closely following the development of IVS. IVS is applicable in many of our valuation engagements looking for consistency and transparency for potential investment decisions.
ARE YOU READY FOR THE POST-COVID-19 IMPACTS?
Many companies still struggle in how to fulfill the requirement to consider forward looking information in the expected credit loss adjustment. Let’s recall the standard’s requirement on this matter.
